HIGHLIGHTS
- who: JHEOR and collaborators from the Non-valvular Atrial Fibrillation in Spain have published the research work: Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with, in the Journal: (JOURNAL)
- what: The aim of this study was to evaluate from the Spanish National Health System perspective the cost-effectiveness of rivaroxaban (20 mg/day) versus use of acenocoumarol (5 mg/day) for the treatment of patients with non-valvular atrial fibrillation (NVAF) at moderate to high risk for stroke. The clinical data obtained in the phase III ROCKET AF . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.